Characterization of Depressive and Anxiety Symptoms in Idiopathic REM Sleep Behavior Disorder.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2021
Historique:
pubmed: 11 5 2021
medline: 29 1 2022
entrez: 10 5 2021
Statut: ppublish

Résumé

Depression and anxiety are common in synucleinopathies and often present during prodromal stages, including idiopathic/isolated REM sleep behavior disorder (iRBD). However, the specific profiles of depression/anxiety and their predictive values for phenoconversion remain unclear. To assess the predominant manifestations, predictive value, and changes over time in depressive and anxiety symptoms in iRBD. Patients with polysomnography-confirmed iRBD (n = 114) and healthy controls (n = 44) were recruited. The Beck Depression Inventory and Beck Anxiety Inventory were administered at baseline, which was repeated prospectively over follow-up. Factor solutions were generated to delineate symptom clusters within the scales, and to help disentangle primary mood symptoms from other neurodegenerative confounds. Total scores, individual scale items, and factors were evaluated to 1) compare patients and controls, 2) assess progression of symptoms over time, and 3) assess predictive value for phenoconversion. At baseline, iRBD patients had more severe depressive (9.0 = 6.7 vs 5.8 = 4.8) and anxiety (7.0 = 7.9 vs 4.5 = 6.0) symptoms than controls. Increased scores were seen in numerous individual scale items and most scales' factors. For depressive symptoms, there was no progression of total scores or factors over time. However, anxiety scores worsened slightly over prospective follow-up (annual slope = 0.58 points, p < 0.05). Over an average 2.4 = 3.1-year follow-up, 37 patients phenoconverted and 72 remained disease-free. Neither baseline depressive nor anxiety symptoms predicted phenoconversion to clinical neurodegenerative disease. Depressive and anxiety symptoms are common in iRBD. However, they do not predict phenoconversion and show only modest progression over time, solely for anxiety.

Sections du résumé

BACKGROUND
Depression and anxiety are common in synucleinopathies and often present during prodromal stages, including idiopathic/isolated REM sleep behavior disorder (iRBD). However, the specific profiles of depression/anxiety and their predictive values for phenoconversion remain unclear.
OBJECTIVE
To assess the predominant manifestations, predictive value, and changes over time in depressive and anxiety symptoms in iRBD.
METHODS
Patients with polysomnography-confirmed iRBD (n = 114) and healthy controls (n = 44) were recruited. The Beck Depression Inventory and Beck Anxiety Inventory were administered at baseline, which was repeated prospectively over follow-up. Factor solutions were generated to delineate symptom clusters within the scales, and to help disentangle primary mood symptoms from other neurodegenerative confounds. Total scores, individual scale items, and factors were evaluated to 1) compare patients and controls, 2) assess progression of symptoms over time, and 3) assess predictive value for phenoconversion.
RESULTS
At baseline, iRBD patients had more severe depressive (9.0 = 6.7 vs 5.8 = 4.8) and anxiety (7.0 = 7.9 vs 4.5 = 6.0) symptoms than controls. Increased scores were seen in numerous individual scale items and most scales' factors. For depressive symptoms, there was no progression of total scores or factors over time. However, anxiety scores worsened slightly over prospective follow-up (annual slope = 0.58 points, p < 0.05). Over an average 2.4 = 3.1-year follow-up, 37 patients phenoconverted and 72 remained disease-free. Neither baseline depressive nor anxiety symptoms predicted phenoconversion to clinical neurodegenerative disease.
CONCLUSIONS
Depressive and anxiety symptoms are common in iRBD. However, they do not predict phenoconversion and show only modest progression over time, solely for anxiety.

Identifiants

pubmed: 33967057
pii: JPD212625
doi: 10.3233/JPD-212625
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1409-1416

Auteurs

Lucy Honeycutt (L)

Department of Neurology, McGill University, Montreal General Hospital, Montreal, 7 QC, Canada.

Jean-François Gagnon (JF)

Centre d'Études Avancées en Médecine du Sommeil, CIUSSS-NÎM-Hĉpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada.

Amélie Pelletier (A)

Centre d'Études Avancées en Médecine du Sommeil, CIUSSS-NÎM-Hĉpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
Department of Neurology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.

Jacques Y Montplaisir (JY)

Centre d'Études Avancées en Médecine du Sommeil, CIUSSS-NÎM-Hĉpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
Department of Psychiatry, Université de Montreal, Montreal, QC, Canada.

Geneviève Gagnon (G)

Department of Psychology, McGill University, Montreal, QC, Canada.

Ronald B Postuma (RB)

Department of Neurology, McGill University, Montreal General Hospital, Montreal, 7 QC, Canada.
Centre d'Études Avancées en Médecine du Sommeil, CIUSSS-NÎM-Hĉpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
Department of Neurology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH